基于草药成分的药物靶点预测:探讨芪参颗粒对冠心病多靶点药理作用机制的研究。
Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of qishenkeli acting on the coronary heart disease.
机构信息
Beijing University of Chinese Medicine, Bei San Huan Dong Lu 11, ChaoYang District, Beijing, China.
出版信息
Evid Based Complement Alternat Med. 2012;2012:698531. doi: 10.1155/2012/698531. Epub 2012 Mar 8.
In this paper, we present a case study of Qishenkeli (QSKL) to research TCM's underlying molecular mechanism, based on drug target prediction and analyses of TCM chemical components and following experimental validation. First, after determining the compositive compounds of QSKL, we use drugCIPHER-CS to predict their potential drug targets. These potential targets are significantly enriched with known cardiovascular disease-related drug targets. Then we find these potential drug targets are significantly enriched in the biological processes of neuroactive ligand-receptor interaction, aminoacyl-tRNA biosynthesis, calcium signaling pathway, glycine, serine and threonine metabolism, and renin-angiotensin system (RAAS), and so on. Then, animal model of coronary heart disease (CHD) induced by left anterior descending coronary artery ligation is applied to validate predicted pathway. RAAS pathway is selected as an example, and the results show that QSKL has effect on both rennin and angiotensin II receptor (AT1R), which eventually down regulates the angiotensin II (AngII). Bioinformatics combing with experiment verification can provide a credible and objective method to understand the complicated multitargets mechanism for Chinese herbal formula.
在本文中,我们通过药物靶点预测和中药化学成分分析,并进行后续的实验验证,以研究中药的潜在分子机制为目的,进行了一项关于芪参益气滴丸(QSKL)的案例研究。首先,确定 QSKL 的组成化合物后,我们使用 drugCIPHER-CS 预测其潜在的药物靶点。这些潜在靶点与已知的心血管疾病相关药物靶点显著富集。然后我们发现这些潜在的药物靶点显著富集在神经活性配体-受体相互作用、氨酰-tRNA 生物合成、钙信号通路、甘氨酸、丝氨酸和苏氨酸代谢以及肾素-血管紧张素系统(RAAS)等生物学过程中。然后,应用左冠状动脉前降支结扎诱导的冠心病动物模型来验证预测的通路。选择 RAAS 通路作为一个例子,结果表明 QSKL 对肾素和血管紧张素 II 受体(AT1R)均有作用,最终下调血管紧张素 II(AngII)。生物信息学结合实验验证可以为理解中药复方的复杂多靶点机制提供一种可靠和客观的方法。
相似文献
Evid Based Complement Alternat Med. 2012-3-8
Evid Based Complement Alternat Med. 2017
J Chromatogr B Analyt Technol Biomed Life Sci. 2021-6-15
引用本文的文献
Front Microbiol. 2023-6-15
Front Pharmacol. 2021-10-7
Evid Based Complement Alternat Med. 2021-4-27
本文引用的文献
Chin J Integr Med. 2011-11-6
Chin J Integr Med. 2010-6
Nucleic Acids Res. 2009-11-6
PLoS Comput Biol. 2009-10-30
Nucleic Acids Res. 2009-10-22
Chin J Integr Med. 2009-10-3
Am J Physiol Renal Physiol. 2009-7-29